A2B receptors mediate the induction of early genes and inhibition of arterial smooth muscle cell proliferation via Epac

Cardiovascular Research

Volumn 90, Issue 1, 2011, Pages 148-156

  Mayer, Peter ^a   Hinze, Annette Viktoria ^a,b   Harst, Anja ^a   Von Kügelgen, Ivar ^b  

^a FEDERAL INSTITUTE FOR DRUGS AND MEDICAL DEVICES   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Adenosine A2B receptor; Arterial smooth muscle cell; Exchange protein activated by cAMP; Nuclear factor NR4A1; Proliferation

Indexed keywords

2 CHLOROADENOSINE; 8 [4 (4 BENZYLPIPERAZIDE 1 SULFONYL)PHENYL] 1 PROPYLXANTHINE; [8 (4 CHLOROPHENYLTHIO) 2' O METHYLCYCLIC ADENOSINE MONOPHOSPHATE; ADENOSINE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A2B RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; ANTIPORTER; CYCLIC AMP DERIVATIVE; DNA; EXCHANGE PROTEIN ACTIVATED BY CYCLIC ADENOSINE MONOPHOSPHATE; FORSKOLIN; NUCLEAR RECEPTOR NUR77; PLATELET DERIVED GROWTH FACTOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ADENOSINE A2 RECEPTOR AGONIST; ADENOSINE A2 RECEPTOR ANTAGONIST; CYCLIC AMP; GUANINE NUCLEOTIDE EXCHANGE FACTOR; NR4A1 PROTEIN, HUMAN; RAPGEF3 PROTEIN, HUMAN;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CORONARY ARTERY; DNA HYBRIDIZATION; GENE EXPRESSION; GENE INDUCTION; HUMAN; HUMAN CELL; IMMEDIATE EARLY GENE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; ADULT; AGED; CELL CULTURE; CORONARY BLOOD VESSEL; DNA MICROARRAY; DOSE RESPONSE; DRUG EFFECT; FEMALE; GENE EXPRESSION PROFILING; GENETIC TRANSFECTION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; METHODOLOGY; MIDDLE AGED; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME; UPREGULATION; VASCULAR SMOOTH MUSCLE;

ADENOSINE; ADENOSINE A2 RECEPTOR AGONISTS; ADENOSINE A2 RECEPTOR ANTAGONISTS; ADULT; AGED; CELL PROLIFERATION; CELLS, CULTURED; CORONARY VESSELS; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION PROFILING; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NUCLEAR RECEPTOR SUBFAMILY 4, GROUP A, MEMBER 1; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTOR, ADENOSINE A2B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; UP-REGULATION;

EID: 79952839205     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvq371     Document Type: Article

References (50)

1. Kennedy C, Burnstock G. Evidence for two types of P2-purinoceptor in longitudinal muscle of the rabbit portal vein. Eur J Pharmacol 1985;111:49-56. (Pubitemid 15097840)
2. von Kügelgen I, Starke K. Noradrenaline and adenosine triphosphate as co-transmitters of neurogenic vasoconstriction in rabbit mesenteric artery. J Physiol 1985;367:435-455. (Pubitemid 16195399)
3. von Kügelgen I, Häussinger D, Starke K. Evidence for a vasoconstriction-mediating receptor for UTP, distinct from the P2 purinoceptor, in rabbit ear artery. Naunyn Schmiedebergs Arch Pharmacol 1987;336:556-660.
4. Olsson RA, Pearson JD. Cardiovascular purinoceptors. Physiol Rev 1990;70:761-845. (Pubitemid 20196050)
5. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev 1998; 50:413-492. (Pubitemid 28477681)
6. Khakh BS, Burnstock G, Kennedy C, King BF, North RA, Seguela P et al. International union of pharmacology. XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits. Pharmacol Rev 2001;53:107-118. (Pubitemid 32173110)
7. Dorsam RT, Kunapuli SP. Central role of the P2Y12 receptor in platelet activation. J Clin Invest 2004;113:340-345. (Pubitemid 38544175)
8. von Kügelgen I. Pharmacological profiles of cloned mammalian P2Y-receptor subtypes. Pharmacol Ther 2006;110:415-432.
9. Guan Z, Osmond DA, Inscho EW. P2X receptors as regulators of the renal microvasculature. Trends Pharmacol Sci 2007;28:646-652. (Pubitemid 350166576)
10. Morato M, Sousa T, Albino-Teixeira A. Purinergic receptors in the splanchnic circulation. Purinergic Signal 2008;4:267-285.
11. Jonzon B, Nilsson J, Fredholm BB. Adenosine receptor-mediated changes in cyclic AMP production and DNA synthesis in cultured arterial smooth muscle cells. J Cell Physiol 1985;124:451-456. (Pubitemid 16242753)
12. Ryzhov S, McCaleb JL, Goldstein AE, Biaggioni I, Feoktistov I. Role of adenosine receptors in the regulation of angiogenic factors and neovascularization in hypoxia. J Pharmacol Exp Ther 2007;320:565-572. (Pubitemid 46147935)
13. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001;53:527-552.
14. Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 2006;5:247-264. (Pubitemid 43336037)
15. Rubino A, Ralevic V, Burnstock G. Contribution of P1-(A2b subtype) and P2-purinoceptors to the control of vascular tone in the rat isolated mesenteric arterial bed. Br J Pharmacol 1995;115:648-652.
16. Rump LC, Oberhauser V, von Kügelgen I. Purinoceptors mediate renal vasodilation by nitric oxide dependent and independent mechanisms. Kidney Int 1988;54:473-481.
17. Hinschen AK, Rose'Meyer RB, Headrick JP. Adenosine receptor subtypes mediating coronary vasodilation in rat hearts. J Cardiovasc Pharmacol 2003;41:73-80. (Pubitemid 36015058)
18. Ansari HR, Nadeem A, Talukder MA, Sakhalkar S, Mustafa SJ. Evidence for the involvement of nitric oxide in A2B receptor-mediated vasorelaxation of mouse aorta. Am J Physiol 2007;292:H719-H725. (Pubitemid 46105235)
19. Shen J, Halenda SP, Sturek M, Wilden PA. Cell-signaling evidence for adenosine stimulation of coronary smooth muscle proliferation via the A1 adenosine receptor. Circ Res 2005;97:574-582. (Pubitemid 41361748)
20. Clark AN, Youkey R, Liu X, Jia L, Blatt R, Day YJ et al. A1 adenosine receptor activation promotes angiogenesis and release of VEGF from monocytes. Circ Res 2007; 101:1130-1138. (Pubitemid 350146439)
21. Edwards JM, Alloosh MA, Long XL, Dick GM, Lloyd PG, Mokelke EA et al. Adenosine A1 receptors in neointimal hyperplasia and in-stent stenosis in Ossabaw miniature swine. Coron Artery Dis 2008;19:27-31. (Pubitemid 351339963)
22. Dubey RK, Gillespie DG, Osaka K, Suzuki F, Jackson EK. Adenosine inhibits growth of rat aortic smooth muscle cells. Possible role of A2b receptor. Hypertension 1996;27: 786-793.
23. Dubey RK, Gillespie DG, Mi Z, Jackson EK. Adenosine inhibits growth of human aortic smooth muscle cells via A2B receptors. Hypertension 1998;31:516-521.
24. Yang D, Koupenova M, McCrann DJ, Kopeikina KJ, Kagan HM, Schreiber BM et al. The A2b adenosine receptor protects against vascular injury. Proc Natl Acad Sci USA 2008; 105:792-796. (Pubitemid 351171787)
25. Yang D, Zhang Y, Nguyen HG, Koupenova M, Chauhan AK, Makitalo M et al. The A2B adenosine receptor protects against inflammation and excessive vascular adhesion. J Clin Invest 2006;116:1913-1923. (Pubitemid 44033315)
26. Grenz A, Osswald H, Eckle T, Yang D, Zhang H, Tran ZV et al. The reno-vascular A2B adenosine receptor protects the kidney from ischemia. PLoS Med 2008;5:e137.
27. Teuscher E, Weidlich V. Adenosine nucleotides, adenosine and adenine as angiogenesis factors. Biomed Biochim Acta 1985;44:493-495.
28. Erlinge D. Extracellular ATP: a growth factor for vascular smooth muscle cells. Gen Pharmacol 1998;31:1-8. (Pubitemid 28239746)
29. Arkenbout EK, de Waard V, van Bragt M, van Achterberg TA, Grimbergen JM, Pichon B et al. Protective function of transcription factor TR3 orphan receptor in atherogenesis: decreased lesion formation in carotid artery ligation model in TR3 transgenic mice. Circulation 2002;106:1530-1535.
30. Mart́nez-González J, Badimon L. The NR4A subfamily of nuclear receptors: new early genes regulated by growth factors in vascular cells. Cardiovasc Res 2005, 65, 609-618.
31. de Waard V, Arkenbout EK, Vos M, Mocking AI, Niessen HW, Stooker W et al. TR3 nuclear orphan receptor prevents cyclic stretch-induced proliferation of venous smooth muscle cells. Am J Pathol 2006;168:2027-2035. (Pubitemid 43825321)
32. Bonta PI, Pols TW, de Vries CJ. NR4A nuclear receptors in atherosclerosis and veingraft disease. Trends Cardiovasc Med 2007;17:105-111. (Pubitemid 46518167)
33. Yoo YG, Na TY, Yang WK, Kim HJ, Lee IK, Kong G et al. Activation of nuclear receptor Nur77 by 6-mercaptopurine protects against neointima formation. Circulation 2007;115:493-500.
34. Kovalovsky D, Refojo D, Liberman AC, Hochbaum D, Pereda MP, Coso OA et al. Activation and induction of NUR77/NURR1 in corticotrophs by CRH/cAMP: Involvement of calcium, protein kinase A, and MAPK pathways. Mol Endocrinol 2002;16: 1638-1651. (Pubitemid 34746009)
35. Maxwell MA, Cleasby ME, Harding A, Stark A, Cooney GJ, Muscat GEO. Nur77 regulates lipolysis in skeletal muscle cells. J Biol Chem 2005;280:12573-12584.
36. Pei L, Waki H, Vaitheesvaran B, Wilpitz DC, Kurland IJ, Tontonoz P. NR4A orphan nuclear receptors are transcriptional regulators of hepatic glucose metabolism. Nat Med 2006;12:1048-1055. (Pubitemid 44353386)
37. Mayer P, Harst A, von Kügelgen I. Early effects of ADP and adenosine on gene expression in human coronary artery vascular smooth muscle cells. Naunyn-Schmiedeberg's Arch Pharmacol 2008;377(Suppl. 1):19-20.
38. Mackay IM, Arden KE, Nitsche A. Real-time PCR in virology. Nucleic Acids Res 2002;30: 1292-1305. (Pubitemid 34679706)
39. Espy MJ, Uhl JR, Sloan LM, Buckwalter SP, Jones MF, Vetter EA et al. Real-time PCR in clinical microbiology: applications for routine laboratory testing. Clin Microbiol Rev 2006;19:165-256. (Pubitemid 43158452)
40. Kubista M, Andrade JM, Bengtsson M, Forootan A, Jonák J, Lind K et al. The real-time polymerase chain reaction. Mol Aspects Med 2006;27:95-125.
41. Hoffmann K, Sixel U, Di Pasquale F, von Kügelgen I. Involvement of basic amino acid residues in transmembrane regions 6 and 7 in agonist and antagonist recognition of the human platelet P2Y12-receptor. Biochem Pharmacol 2008;76:1201-1213.
42. Yan L, Bertarelli DC, Hayallah AM, Meyer H, Klotz KN, Müller CE. A new synthesis of sulfonamides by aminolysis of p-nitrophenylsulfonates yielding potent and selective adenosine A2B receptor antagonists. J Med Chem 2006;49:4384-4391. (Pubitemid 44036682)
43. Kim YC, Ji Xd, Melman N, Linden J, Jacobson KA. Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A2B adenosine receptors. J Med Chem 2000;43:1165-1172. (Pubitemid 30173742)
44. Christensen AE, Selheim F, de Rooij J, Dremier S, Schwede F, Dao KK et al. cAMP analog mapping of Epac1 and cAMP kinase. Discriminating analogs demonstrate that Epac and cAMP kinase act synergistically to promote PC-12 cell neurite extension. J Biol Chem 2003;278:35394-35402. (Pubitemid 37102308)
45. Kase H, Iwahashi K, Nakanishi S, Matsuda Y, Yamada K, Takahashi M et al. K-252 compounds, novel and potent inhibitors of protein kinase C and cyclic nucleotidedependent protein kinases. Biochem Biophys Res Commun 1987;142:436-440. (Pubitemid 17003365)
46. Nomiyama T, Nakamachi T, Gizard F, Heywood EB, Jones KL, Ohkura N et al. The NR4A orphan nuclear receptor NOR1 is induced by platelet-derived growth factor and mediates vascular smooth muscle cell proliferation. J Biol Chem 2006;281: 33467-33476. (Pubitemid 46036728)
47. Kiss I, Oskolás H, Tóth R, Bouillet P, Tóth K, Fülöp A et al. Adenosine A2A receptormediated cell death of mouse thymocytes involves adenylate cyclase and Bim and is negatively regulated by Nur77. Eur J Immunol 2006;36:1559-1571. (Pubitemid 43942144)
48. Martin LJ, Boucher N, El-Asmar B, Tremblay JJ. cAMP-induced expression of the orphan nuclear receptor Nur77 in MA-10 Leydig cells involves a CaMKI pathway. J Androl 2009;30:134-145.
49. Fang Y, Olah ME. Cyclic AMP-dependent, protein kinase A-independent activation of extracellular signal-regulated kinase 1/2 following adenosine receptor stimulation in human umbilical vein endothelial cells: role of exchange protein activated by cAMP 1 (Epac1). J Pharmacol Exp Ther 2007;322:1189-1200. (Pubitemid 47295788)
50. deWaard V, Arkenbout EK, Vos M, Mocking A, Niessen HWM, StookerWet al. TR3 nuclear orphan receptor prevents cyclic stretch-induced proliferation of venous smooth muscle cells. Am J Pathol 2006;168:2027-2035. (Pubitemid 43825321)